Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Markets:
Overview
News
Currencies
International
Treasuries

Can-Fite Biopharma Ltd Sponsored ADR (Israel) (NY:CANF)

0.3433 +0.0073 (+2.17%)
Streaming Delayed Price Updated: 3:54 PM EST, Nov 26, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about Can-Fite Biopharma Ltd Sponsored ADR (Israel)

< Previous 1 2 3 4 5 6 7 Next >
News headline image
Can-Fite Receives U.S. FDA’s Go Ahead for Piclidenoson Psoriasis Registration Plan
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Submit IND for the Treatment of Pancreatic Cancer Patients with Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Participate in Out-licensing and Distribution Partnering Meetings at Bio International Convention in Boston
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Recap: Can Fite Biofarma Q1 Earnings ↗
 
Via Benzinga
News headline image
Can-Fite Reports First Quarter 2023 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite: Namodenoson’s Inhibition of Pancreatic Carcinoma Receives Recognition from the American Society of Clinical Oncology (ASCO)
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite: Presenting Namodenoson’s New Pancreatic Cancer Indication to Potential Partners at BioEquity Europe 2023
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Initiate Exploratory Phase 2 Trial with Namodenoson in Pancreatic Cancer Patients
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
12 Health Care Stocks Moving In Friday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Can-Fite BioPharma Spikes on Pancreatic Cancer Inhibition Finding
Can-Fite BioPharma Ltd. (NYSEAMERICAN: CANF) is an Israel-based biotechnology firm that develops small-molecule therapeutic treatments for cancers 
Via MarketBeat
News headline image
12 Health Care Stocks Moving In Tuesday's Pre-Market Session ↗
 
Via Benzinga
News headline image
Inhibition of Pancreatic Cancer by Namodenoson: Molecular Mechanism of Action Discovered by Can-Fite Scientists
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Announces New Management Structure as Advanced Stage Pipeline Moves Toward Commercialization
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Today’s Biggest Pre-Market Stock Movers: 10 Top Gainers and Losers on Thursday ↗
It's time for another dive into the biggest pre-market stock movers as we see what's moving the market on Thursday morning! 
Via InvestorPlace
News headline image
12 Health Care Stocks Moving In Tuesday's Intraday Session ↗
 
Via Benzinga
News headline image
Can-Fite: EMA Gives Green Light for Piclidenoson Pivotal Phase III Clinical Trial for Psoriasis Treatment
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Revenue FY22 Revenue Declines 4.7%, Here Is What You Need To Know ↗
Can-Fite BioPharma Ltd. (AMEX:CANF) (TASE:CANF) revenues for the year ended December 31, 2022 were $810,000, a decrease of $43,000, or 4.7%, compared to revenues of $853,000 during the twelve months... 
Via Benzinga
News headline image
Can-Fite Reports 2022 Financial Results & Provides Clinical Update
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Conduct Meetings at the BIO-Europe Spring Conference with Pharma Companies Interested in Licensing and Distributing Piclidenoson and Namodenoson
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite to Treat Decompensated Liver Cirrhosis Patients with Namodenoson Under Compassionate Use Setting
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Tuesday ↗
  During Tuesday, 40 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Novel Approach to Treating Advanced Liver Cancer with Namodenoson Published in Leading Scientific Journal: 12-Month Survival of 44% for Namodenoson vs. 18% for Placebo
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Friday ↗
  During Friday, 48 stocks hit new 52-week lows. 
Via Benzinga
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 22 companies hit new 52-week lows. 
Via Benzinga
News headline image
Can-Fite: Namodenoson Significantly Inhibits Pancreatic Cancer in Preclinical Studies—A Patent Has Been Filed
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Announces $7.5 Million Concurrent Registered Direct Offering and Private Placement
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite Submits Market Registration Plan to European Medicines Agency for Piclidenoson in the Treatment of Psoriasis; FDA Submission to Follow
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Stocks That Hit 52-Week Lows On Wednesday ↗
  On Wednesday, 35 companies reached new 52-week lows. 
Via Benzinga
News headline image
Can-Fite Announces ADS Ratio Change
From Can-Fite BioPharma Ltd.
Via Business Wire
News headline image
Can-Fite's Namodenoson Increases Survival For Most Severe Patients With Advanced Liver Cancer ↗
 
Via Benzinga
< Previous 1 2 3 4 5 6 7 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the Privacy Policy and Terms Of Service.
© 2025 FinancialContent. All rights reserved.